Background: Cancer screening rates are often lower among racial and ethnic subgroups compared to Whites. Additionally, public health surveys often survey in English and may not reflect limited English proficient, immigrant populations.

Methods: The Cancer community health resources and needs assessment (CHRNA) was administered from October 2021 to December 2022 among diverse racial/ethnic groups within NYU Langone Perlmutter Cancer Center’s catchment area. Online survey administration was performed using REDCap in English, Arabic, Bangla, Chinese (Simplified/Traditional), Haitian Creole, Korean, Spanish, Russian, and Urdu. Outcomes for this analysis included mammography among women ≥40 in the past 2 years, Pap test among women in the past 3 years, and colonoscopy screening among individuals ≥50 in the past 10 years, in order to match outcomes from the New York City Community Health Survey (NYC CHS) EpiQuery. A data use agreement is in progress with the NYC Department of Health and Mental Hygiene to access disaggregated Asian, Hispanic, and Black subgroup data. Final results from NYC CHS will include 2017 Pap test, 2019 mammogram, and 2016-2020 colonoscopy screenings; and screening outcomes will be compared to the Cancer CHRNA data.

Results: The Cancer CHRNA data—mammogram (n=870), Pap test (n=1,496), and colonoscopy (n=951) —were compared to online data from 2014 and 2017 NYC CHS EpiQuery. The majority of cancer screening rates were lower in the Cancer CHRNA compared to the NYC CHS, especially among Blacks (Haitians), Hispanics, Whites (Eastern Europeans), and Asians (Chinese, Korean, and Bangladeshi). For example, up-to-date Pap test was 66.8% among Asians/Pacific Islanders in the NYC CHS, compared to 44.7% in the Cancer CHRNA (Chinese: 46.1%, Korean: 34.1%, Bangladeshi: 50.5%). Final results will compare all cancer screening outcomes across available subgroups in both datasets.

Conclusion: Our preliminary results found that cancer screening rates were much lower in our diverse, largely immigrant NYC population.